Evaluation of the safety and efficacy of using human menstrual blood‐derived mesenchymal stromal cells in treating severe and critically ill COVID‐19 patients: An exploratory clinical trial

The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and has subsequently spread worldwide. Currently, there is no effective method to cure COVID‐19. Mesenchymal stromal cells (MSCs) may be able to effectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xiaowei, Jiang, Wanli, Chen, Lijun, Xu, Zhenyu, Zhang, Qiang, Zhu, Mengfei, Ye, Peng, Li, Hang, Yu, Liang, Zhou, Xiaoyang, Zhou, Chenliang, Chen, Xiaobei, Zheng, Xiaoqin, Xu, Kaijin, Cai, Hongliu, Zheng, Shufa, Jiang, Wubian, Wu, Xiaojun, Li, Dong, Chen, Lu, Luo, Qingqing, Wang, Yingyan, Qu, Jingjing, Li, Yifei, Zheng, Wendi, Jiang, Yingan, Tang, Lingling, Xiang, Charlie, Li, Lanjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839959/
https://www.ncbi.nlm.nih.gov/pubmed/33634996
http://dx.doi.org/10.1002/ctm2.297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839959/
https://www.ncbi.nlm.nih.gov/pubmed/33634996
http://dx.doi.org/10.1002/ctm2.297

Ejemplares similares